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Benzene is a clastogenic and carcinogenic agent that induces acute myelogenous leukemia in
humans and multiple types of tumors in animals. Previous research has indicated that benzene
must first be metabolized to one or more bioactive species to exert its myelotoxic and genotoxic
effects. To better understand the possible role of individual benzene metabolites in the leuke-
mogenic process, as well as to further investigate inhibition of topoisomerase 11 by benzene
metabolites, a series of known and putative benzene metabolites, phenol, 4,4'-biphenol, 2,2'-
biphenol, hydroquinone, catechol, 1,2,4-benzenetriol, 1,4-benzoquinone, and trans-trans-
muconaldehyde were tested for inhibitory effects in vitro on the human topoisomerase 11
enzyme. With minor modifications of the standard assay conditions, 1,4-benzoquinone and trans-
trans-muconaldehyde were shown to be directly inhibitory, whereas all of the phenolic metabo-
lites were shown to inhibit enzymatic activity following bioactivation using a peroxidase activation
system. The majority of compounds tested inhibited topoisomerase 11 at concentrations at or
below 10 pM. These results confirm and expand upon previous findings from our laboratory and
indicate that many of the metabolites of benzene could potentially interfere with topoisomerase
11. Since other inhibitors of topoisomerase 11 have been shown to induce leukemia in humans,
inhibition of this enzyme by benzene metabolites may also play a role in the carcinogenic effects
of benzene. Environ Health Perspect 104(Suppl 6):1319-1323 (1996)
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Introduction
Benzene is a known leukemia-inducing
agent in humans and a multisite carcinogen
in rodents (1). However, the mechanisms
by which benzene exerts its leukemogenic
effects remain unknown. A number of
studies have shown that benzene-exposed
workers exhibit increased frequencies of
structural and numerical chromosome
aberrations in their peripheral blood and
bone marrow cells (2,3). In addition, ani-
mal studies have shown that after benzene
exposure, increases in micronuclei, chro-
mosome loss, and breakage are seen in the
hematopoietic cells of mice and rats
(1,4,5). These chromosomal effects, com-
bined with observations that benzene is
only weakly mutagenic in standard gene
mutation assays (6,7) and binds poorly to
DNA (8,9) suggest that indirect genetic
mechanisms that result in translocations,
deletions, aberrant recombination, or aneu-
ploidy may be important in benzene's
genotoxic effects (10,11). It is also likely
that the chromosome damage seen in the
blood cells ofoccupationally exposed pop-
ulations reflects alterations occurring in the
hematopoietic stem cells, which contribute
to leukemogenesis. In addition to benzene,
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a number of different types of leukemia-
inducing agents have been identified (12).
Topoisomerase-interactive agents make up
one recently identified class of leuke-
mogens that exhibit similarities to benzene
in their cellular, genotoxic, and leuke-
mogenic effects (13).
Topoisomerase II enzymes relieve tor-
sional strain on DNA that occurs during
replication and transcription by creating
transient breaks in both strands ofdouble-
stranded DNA and allowing passage of a
second DNA strand (14).These enzymes
are also important structural components
of interphase nuclei and are believed to
function during recombination and chro-
mosome condensation (14,15). Over the
past several years, a number ofpotent anti-
cancer drugs have been identified that tar-
get topoisomerase II (16). These drugs can
be divided up into three distinct groups.
First are the intercalating compounds such
as the drug classes of anthracyclines,
amsacrines, and ellipticines that stimulate
the formation of the cleavable complex
(17). Second are the epipodophyllotoxins,
which form the cleavable complex, but do
not intercalate into DNA (17). A third
class ofcompounds has been identified in
the last few years that includes compounds
such as the dioxopiperazine and coumarin
derivatives merbarone and novobiocin that
inhibit topoisomerase II activity but do not
intercalate or induce formation ofthe cleav-
able complex (15,17-19).These topoiso-
merase II-interactive agents (referred to here
as "topoisomerase inhibitors") act through a
variety ofdifferent mechanisms including
the prevention oftopoisomerase II binding
to DNA, inhibition ofstrand passage, stabi-
lization ofthe enzyme-DNA complex, or
interference with the religation ofthe DNA
strands (14). Topoisomerase II inhibitors
tend to be strong clastogens in mammalian
cells (14,20). In addition, these agents have
been shown to induce sister chromatid
exchanges and illegitimate recombination as
well as inhibit chromosome separation and
DNA and RNA synthesis (14,20). These
inhibitors have also been demonstrated to
delay cells in the G2 to M phases ofthe cell
cycle, altering differentiation and perturb-
ing the topoisomerase enzyme, thus render-
ing it error prone (14,16,21-23).
Previous work in our laboratory has
shown that some ofthe known and putative
metabolites of benzene inhibit topoiso-
merase II in vitro at relatively high concen-
trations (13). Using a model peroxidase
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activation system similar to the system
believed to exist in the bone marrow
(24,25), inhibition was also seen at much
lower concentrations with phenol, 2,2'-
biphenol and 4,4'-biphenol. Based on these
observations, we proposed that inhibition
of topoisomerase II may contribute to the
clastogenic and carcinogenic effects ofben-
zene (13). These initial studies were con-
ducted using the standard topoisomerase
assay protocol recommended by the sup-
plier ofthe enzyme. In addition, high per-
oxidase concentrations were employed for
bioactivation with incubations being per-
formed for 1 hr to ensure that metabolism
was complete and to minimize effects due
to short-lived radical species. In these ear-
lier studies, reduced glutathione (GSH)
was shown to protect the topoisomerase
enzyme from inhibition by activated
4,4'-biphenol in spite of the presence of
dithiothreitol in the assay buffer. This sug-
gested that the assay conditions might
significantly influence the outcome ofthe
topoisomerase assay. Furthermore, subse-
quent spectrophotometric studies indicated
that activation occurred very rapidly, which
mayhave affected the assay results byallow-
ing degradation ofthe reactive intermedi-
ates during the remaining 1-hr incubation.
In this study, the peroxidase concentrations
and incubation times were shortened to
reduce these possibilities. In addition,
metabolites that we had not previously
tested with metabolic activation were tested
for inhibitory effects after incubation with a
peroxidase activation system. The results of
these studies demonstrate that a variety of
reactive metabolites ofbenzene are capable
ofinhibiting topoisomerase II in vitrowhen
tested under appropriate assayconditions or
withperoxidase activation.
Materials and Methods
Phenol, hydroquinone, catechol, 1,4-ben-
zoquinone, 1,2,4-benzenetriol, 2,2'-biphe-
nol, and 4,4'-biphenol (all . 98% purity)
were purchased fromAldrich Chemical Co.
(Milwaukee, WI). Glutathione (GSH
reduced form, 98-100%), hydrogen perox-
ide (H202; 30%), horseradish peroxidase
(HRP), type VI (250 U/mg) were obtained
from Sigma Chemical Co. (St. Louis, MO).
Distilled deionized water was obtained
from MallinKrodt Chemical, Inc. (Paris,
KT) trans-trans-Muconaldehyde was a
generous gift of Dr. G. Witz (Rutgers
University, Piscataway, NJ). Human topoi-
somerase II, catenated kinetoplast DNA
(kDNA), and m-amsacrine were obtained
from TopoGEN, Inc. (Columbus, OH).
2,2'-Biphenol, 4,4'-biphenol, and m-
amsacrine were dissolved in 100%
dimethylsulfoxide (DMSO) at 100 mM
concentrations, with subsequent dilutions
in 1% DMSO. trans-trans-Muconaldehyde
was dissolved and diluted in 100% ethanol.
Phenol, hydroquinone, catechol, 1,4-ben-
zoquinone, and 1,2,4-benzenetriol were
prepared in distilled, deionized H20.
Chemical concentrations are reported as
final nominal concentrations in the total
assay volume. The initial concentration to
which the enzyme is exposed will vary
depending on the order that the reaction
components were added.
An HRP solution [1 U/pl] was pre-
pared in 0.1 M Tris-Cl, pH 8. All dilutions
ofperoxidase and H202 solutions were
made in distilled, deionized water. The
final enzyme and H202 concentrations for
all the incubations except those containing
2,2'-biphenol were 0.07 U/ml HRP and
55 pM H202. 2,2'-Biphenol was bioacti-
vated with 0.1 U/ml HRP and 55 pM
H202 concentrations to facilitate more
complete metabolism. Peroxidase bioacti-
vation reactions were run for 5 min at
room temperature, with the exception that
the 2,2'-biphenol incubations were per-
formed for 30 min. Each reaction tube was
then placed on ice, at which time the assay
buffer, kDNA, and topoisomerase II
enzyme were added sequentially for the
topoisomerase assay.
The testing ofbenzene metabolites was
done using a commercially available topoi-
somerase II inhibition assay (TopoGEN).
The kit included purified human topoiso-
merase II (2 U/pl), kDNA (0.1 pg/pl),
decatenated kinetoplast DNA, and 1Ox
assay buffer [0.5 M Tris-Cl, pH 8.0, 1.2 M
KCI, 100 mM MgCl2, 5 mM ATP, 5 mM
dithiothreitol, and 300 pg/mi bovine
serum albumin (BSA)]. Assays were per-
formed in the presence and absence oftest
chemicals or solvents (1 pl added to assay)
by mixing 4 U enzyme with 0.2 pg kDNA
and 3 pl lOx assaybuffer. The reaction was
brought to a final volume of 30 pl with
deionized, distilled H20 (0.2 pm filtered).
For the standard assay method, the order
of addition to the assay was H20, 1Ox
assay buffer, followed by either the test
compound, the solvent, or the metabolic
reaction mixture, kDNA and topoiso-
merase II. For the direct method, the
metabolite or the reaction mix was added
directly to the topoisomerase II, followed
by H20, lOx assay buffer, and kDNA.
The incubations were run for 1 hr at 37°C,
and the reaction was terminated by adding
6 pl of a stop solution consisting of 5%
sarkosyl, 0.0025% bromophenol blue, and
25% glycerol in H20. The DNA products
and decatenated marker kDNA were sepa-
rated by electrophoresis using a 1% agarose
gel and lx (Tris-acetate-EDTA [TAE]
[0.04 M Tris-acetate, 0.001 M EDTA])
buffer containing 0.03 pg/ml ethidium bro-
mide. The DNA-containing bands were
visualized using an ultraviolet light box. All
experiments were repeated a minimum of
three times.
Results
Topoisomerase II activity was determined
by assaying the decatenation of kDNA.
After electrophoresis, the appearance of
either open circular or linearized kDNA
indicated an active and functional enzyme.
Ifinhibition occurred, the kDNA remained
in the catenated form and did not migrate
from the well (13,26). All ofthe benzene
metabolites that were tested inhibited the
ability of topoisomerase II to decatenate
kDNA. The inhibitors fell into two distinct
classes, each ofwhich are described below.
The first group consisted of metabolites
that were inhibitorywhen added directly to
the enzyme. The second and larger group
of metabolites required bioactivation by
peroxidase enzymes to inhibit topoiso-
merase or for inhibition to be seen at low
micromolar concentrations. For this sec-
ond group ofinhibitors, the order in which
the reagents were added to the topoiso-
merase II assay did not substantially alter
the inhibitoryeffects.
1,4-Benzoquinone and trans-trans-
muconaldehyde inhibited topoisomerase II
when added directly to the enzyme before
addition of the assay buffer and kDNA.
This modified reaction assembly proce-
dure was necessary to prevent 1,4-benzo-
quinone and trans-trans-muconaldehyde
from reacting with components of the
assay buffer. When these two compounds
were mixed with the buffer before enzyme
addition, the inhibitory effects were greatly
reduced. Spectrophotometric studies (data
not shown) indicated that dithiothreitol
reacts directly with these benzene metabo-
lites to form UV-absorbing products.
When the reaction was assembled using the
standard procedure, sulfhydryl groups of
dithiothreitol almost certainly reacted with
these two electrophilic chemicals, prevent-
ing them from interacting with topoiso-
merase II and inhibiting its enzymatic
activity. Table 1 shows the metabolites and
concentrations tested and indicates the con-
centrations at which inhibitory effects were
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Table 1. Direct inhibitors oftopoisomerase 11.
Chemical Concentration, pM Inhibitiona
1,4-Benzoquinone 500 ++
100 ++
10 +
1 _
t-t-Muconaldehyde 100 ++
10 +/-
m-Amsacrine 3000 ++
(positive control)
Ethanol control 3.3%(v/v)
Watercontrol 3.3%(v/v)
The benzene metabolites 1,4-benzoquinone and trans-
trans-muconaldehyde were added directly to the topoi-
somerase 11 enzyme with the lOx assay buffer, kDNA,
and water being added shortly thereafter. The reaction
was initiated by placing the reaction tube into a 37°C
water bath for 1 hr. "Inhibition reported as: ++ = total
inhibition; + = partial inhibition; - = no inhibition of
enzyme activity; +/-= inconsistent inhibitory results.
seen. 1,4-Benzoquinone inhibited topoiso-
merase II at concentrations . 10 pM.
trans-trans-Muconaldehyde exhibited con-
sistent inhibitory effects at concentrations
> 100 pM. Inhibition of topoisomerase II
was also seen at lower concentrations, but
the effects were somewhat inconsistent.
Phenol, 4,4'-biphenol, 2,2'-biphenol,
hydroquinone, catechol, and 1,2,4-benzen-
etriol all required bioactivation by peroxi-
dase in the presence ofhydrogen peroxide
to inhibit topoisomerase II at low micro-
molar concentrations. Table 2 shows the
concentrations tested and the concentra-
tions at which inhibitory effects were seen.
Direct addition ofthe metabolic products to
the topoisomerase did not substantially alter
the inhibitory concentrations. 2,2'-Biphenol
was the only compound from this group to
give somewhat variable results. Activated
2,2'-biphenol consistently inhibited topoiso-
merase II at concentrations . 100 pM.
However, inconsistent results were seen at
the lower 10pM concentration.
Discussion
The results ofthese in vitro assays demon-
strate that most ofthe benzene metabolites
are capable ofinhibiting topoisomerase II in
vitro at relatively low concentrations and
indicate that a variety ofbenzene metabo-
lites may be involved in the inhibition of
this enzyme in vivo. For the reactive ben-
zene metabolites 1,4-benzoquinone and
trans-trans-muconaldehyde, inhibition
occurred when the assay was modified so
that the metabolites were added directly to
the topoisomerase II enzyme. For the
phenolic metabolites, incubation in the
Table 2. Metabolites of benzene requiring peroxidase
activation in orderto inhibit topoisomerase 11.
Chemical Concentration, pM Inhibitiona
Phenol 100 ++
10 ++
1 _
4,4'-Biphenol 100 ++
10 ++
1 _
2,2'-Biphenol 100 ++
10 +/-
Hydroquinone 100 ++
10 ++
1 +
0.1 -
Catechol 100 ++
10 ++
1 _
1,2,4-Benzenetriol 100 ++
10 ++
1 _
m-Amsacrine 3000 ++
(positive control)
Controlsb
All the compounds in this table, with the exception of
2,2'-biphenol, were incubated with 0.07 U/ml horse-
radish peroxidase and 55 pM hydrogen peroxide for 5
min, followed by the addition of the lOx assay buffer,
kDNA, and topoisomerase 11 enzyme. 2,2'-Biphenol
was incubated with 0.1 U/ml horseradish peroxidase
and 55 pM hydrogen peroxide; all other steps were the
same. "Inhibition reported as: ++, total inhibition; +,
partial inhibition; -, no inhibition of enzyme activity;
+/-, inconsistent inhibitory results. bControls consisted
of horseradish peroxidase (0.07-0.1 U/ml), H202 (55
pM), and dimethylsulfoxide (0.03-3.3%) orwater.
presence ofa peroxidase/hydrogen peroxide
activation system was necessary for inhibi-
tion of topoisomerase II to be seen at low
micromolar concentrations. The rationale
for the use of a peroxidase activation sys-
tem is that the bone marrow contains high
levels of myeloperoxidase as well as other
peroxidase enzymes (27,28) and increases
in oxygen radicals have been shown to
occur in this organ after benzene adminis-
tration (10,29). In addition, relatively high
levels of phenolic metabolites have been
recovered in the bone marrow after ben-
zene exposure (30).
Recently, a number ofbenzene metabo-
lites were screened by our laboratory for
their inhibitory effects on human topoiso-
merase I and II in vitro (13). In these
initial experiments, assay conditions rec-
ommended by the supplier of the enzyme
were used as well as relatively long (1-hr)
bioactivation incubations with high levels
of peroxidase enzymes. In the studies
reported here, shorter bioactivation periods
(5 min) with reduced enzyme concentra-
tions were used. The results ofthe two series
ofexperiments are quite consistent but illus-
trate how modifications in the assay condi-
tions can significantly alter the test results.
For example, by adding 1,4-benzoquinone
directly to the enzyme, inhibition was seen
at a 10 pM (final) concentration, whereas
inhibition was only seen at 500 pM when
this reactive metabolite was added to the
dithiothreitol- and BSA-containing buffer.
In addition, by altering the bioactivation
procedure, inhibition oftopoisomerase II
was seen at lower concentrations for phenol,
2,2'-biphenol and 4,4'-biphenol.
While the majority of the compounds
assayed in these studies were inhibitory at
10 pM, two ofthe compounds, trans-trans-
muconaldehyde and 2,2'-biphenol, required
higher concentrations (100 pM) to consis-
tently inhibit the topoisomerase enzyme.
However, these compounds were sometimes
observed to inhibit the enzyme at lower
concentrations. We believe that these some-
what inconsistent results were due to insta-
bility of trans-trans-muconaldehyde in
aqueous solutions and the incomplete
metabolism and formation ofpolymers in
incubations containing 2,2'-biphenol.
Attempts to use higher concentrations of
peroxidase and H202 to complete the
metabolism of2,2'-biphenol were problem-
atic in that occasionally inhibition oftopoi-
somerase II was observed in the absence of
added inhibitors, making interpretation of
the experiments difficult. However, at the
0.07 to 0.1 U/ml HRP and 55 pM hydro-
gen peroxide concentrations used for bioac-
tivation in the experiments described here,
this problem was not seen. As a result ofthe
reactive nature and instability of certain
metabolites, the likely presence of nucle-
ophilic constituents in the topoisomerase-
containing solution as well as the influence
ofthe assay conditions, we believe that the
absolute inhibitory concentrations observed
in the topoisomerase II assay should be
interpreted with caution.
The inhibitory effects seen with
1,4-benzoquinone, trans-trans-muconalde-
hyde, and the bioactivated phenolic metabo-
lites as well as observed protection of the
enzyme from inhibition by GSH (13) sug-
gest that there is a sulfhydryl or other
nucleophilic residue on the topoisomerase
enzyme that is critical for enzymatic activity.
These results also indicate that the standard
assay conditions used to screen pharmaceu-
tical and toxicological agents for topoiso-
merase-inhibitory activity may not detect
certain classes of inhibitory compounds
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such as those that react with dithiothreitol
or other components ofthe topoisomerase
assay. Despite the limitations inherent in
the in vitro assay, it is still clear that most of
the benzene metabolites (known and puta-
tive) tested inhibited topoisomerase II in
vitro in the low micromolar concentration
range when assayed under appropriate test
conditions orwith metabolic activation.
Beyond these early in vitro studies, there
is also mounting evidence in the literature
suggesting that topoisomerase II inhibition
may contribute to benzene-induced leuke-
mogenesis. While the evidence is inconclu-
sive at this point, there are a number of
similarities in characteristics exhibited by
the chemotherapeutic topoisomerase II
inhibitors and benzene (or its metabolites)
(Table 3). In addition, topoisomerase II
inhibitors induce high frequencies ofchro-
mosome alterations which are due, at least
in part, to action on specific DNA recogni-
tion sites (31,32). Disrupting topoisomerase
II function frequently results in chromo-
some translocations and deletions, including
alterations affecting chromosome regions
1lq23 and 21q22, which have become hall-
marks oftherapy-related acute myelogenous
leukemia induced by topoisomerase
inhibitors (12,33,34). Translocations have
been reported in the blood cells ofworkers
exposed to benzene and in patients who
have developed leukemia after exposure to
benzene or benzene-containing solvents
such as petroleum (35-40). In a number of
these cases, the translocations and deletions
that have been reported are identical to
those that are characteristic of topoiso-
merase-interactive agents (Table 4). It
should be noted, however, that chromosome
Table 3. Similar characteristics of benzene and selected topoisomerase 11 inhibitors.
Characteristic References
Parent or metabolite has a phenolic orquinonoid structure (6,14,16,17,24,44)
Increased toxicityto actively dividing cells (14,45,46)
Alter differentiation of immature myeloid cells (21,46,47)
Block dividing cells at G2/M stage (13,14,23,45)
Yield high frequencies of structural chromosomal alterations (2,4,12,14,48)
Induce acute myelogenous leukemia (2,1233,34,44,46)
Table 4. Chromosome alterations characteristic of topoisomerase 11 inhibitors reported in leukemia patients with
previous exposure to benzene-containing solvents.
Sex Age Chromosome alteration Source of benzene exposure Reference
Male 37 t(8;21)(q22;q22) Petroleum products (37)
Male 36 t(8;21)(q22;q22) Petroleum products (37)
Male 19 del(l1)(q23;q25) Petroleum products (37)
Female 55 t(4;11)(q21;q23) Benzene-containing solvents (38)
Male 64 t(3;21)(q26.2;q22.1) Benzene-containing solvents (39)
alterations similar to those seen after treat-
ment with alkylating chemotherapeutic
agents such as loss ofall or part ofthe long
arms of chromosomes 5 and 7 (12) have
been reported in benzene-exposed workers
as well as in leukemia patients previously
exposed to benzene (35,40,41). In addition,
trisomy or tetrasomy ofa C-group chromo-
some, occasionally identified as chromo-
some 8 or 9, has been associated with
benzene exposure (11,40,42,43). This
suggests that multiple types and mecha-
nisms ofgenotoxicity may be occurring.
Our currentworking hypothesis is that both
the alkylating-type ofchromosomal alter-
ations (aneuploidy and deletions) as well as
topoisomerase-type alterations (transloca-
tions and deletions) are occurring in ben-
zene-exposed individuals. The combination
ofthese types ofchromosomal alterations
confers increased risks for leukemia similar
to that reported for cancer patients who
have been treated with both alkylating
agents and topoisomerase inhibitors (34).
In summary, our in vitro topoisomerase
II inhibition results, combined with the
characteristics shared by both the bioactive
benzene metabolites and topoisomerase II
inhibitors in addition to the karyotypic
alterations seen in benzene-exposed indi-
viduals, provide support for the hypothesis
that interference with the normal function
oftopoisomerase II is involved in benzene-
induced leukemia. Additional studies are
currently being performed to identify the
species involved in topoisomerase inhibi-
tion in vitro and to determine whether
inhibition oftopoisomerase enzymes con-
tribute to the myelotoxic and carcinogenic
effects ofbenzene in vivo.
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